---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-020876"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:47:01.739587+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech secures additional $343K loan from AlpineBrook; total note principal rises to $27.1M

## Summary
- Additional $343,000 loan from AlpineBrook Capital; total secured note principal increased to $27,101,106.
- Loan funded on Feb 20, 2026; interest accrues from that date.
- This is the fifth amendment to the note, with prior amendments in January 2026.
- Borrowers include NKGen Biotech and NKGen Operating Biotech; CEO Paul Song signed.

## SEC filing metadata
- accession: 0001213900-26-020876
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/ea0277453-8k_nkgenbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-020876
- JSON: https://secwatch.observer/filing/0001213900-26-020876.json
- Plain text: https://secwatch.observer/filing/0001213900-26-020876.txt

## Key facts
- Debt Financings
  NKGen Biotech, Inc. incurred loan of $343,000 with AlpineBrook Capital GP I Limited.
  - Instrument: loan
  - Principal: $343,000
  - Counterparty: AlpineBrook Capital GP I Limited
  - Event: incurrence
  source text: The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the "Fifth Additional New Loan"). As a result, the principal amount of the Note was increased to $27,101,106.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm
- Material Agreements
  NKGen Biotech, Inc. amended Alpine Fourth Amendment with AlpineBrook Capital GP I Limited valued at $343,000 (effective 2026-02-20).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: AlpineBrook Capital GP I Limited
  - Value: $343,000
  - Effective: 2026-02-20
  source text: On February 20, 2026, NKGen Biotech, Inc. (the “Company”) and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a fourth amendment (the “Alpine Fourth Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026, that certain amendment no. 2 to secured promissory note dated January 23, 2026, and that certain amendment no. 3 to secured promissory note dated January 30, 2026 (the “Note”). The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the “Fifth Additional New Loan”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390026020876/0001213900-26-020876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.